Calgary, Alberta - TheNewswire - November 24, 2021. Ocumetics Technology Corp. (TSXV:OTC) (the “Corporation”) announces that it has issued 541,317 incentive stock options to its newest director, Sandi Gilbert. Each option entitles the holder to purchase one common share in the capital of the Corporation at an exercise price per common share of $0.60 for a period of five years. The options will vest over a period of three years, with 15% of the options vesting six months after the date of issuance, another 15% vesting after 12 months, another 35% after 24 months and the remaining 35% after 36 months.
The stock options are not transferrable. The common shares issued upon exercise of the stock options will be subject to a four-month resale restriction from the date of grant.
Ocumetics Technology Corp. (TSXV:“OTC”) is a Canadian research and product development company that specializes in adaptive lens designs. Ocumetics is in the clinical trial stage of a game-changing technology for the ophthalmic industry - the Bionic Lens. The Bionic Lens is an expandable intraocular lens that fits within the natural lens compartment of the eye to completely eliminate the need for corrective lenses. It re-establishes the natural kinetics of the eye muscles to facilitate the eye’s ability to shift focus effortlessly from distance to near and very near range.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dr. Mark Lee
President and CEO
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
Copyright (c) 2021 TheNewswire - All rights reserved.